
LifeMD (LFMD) Stock Forecast & Price Target
LifeMD (LFMD) Analyst Ratings
Bulls say
LifeMD is well positioned for growth in the telehealth industry with a diverse portfolio of brands, partnerships with major pharmaceutical companies and a focus on women's health. However, potential challenges include intense competition and potential difficulties in retaining patients. The recent partnership with Hims & Hers Health and the introduction of a new obesity treatment could drive revenue growth, but potential risks may affect their projected 12-month price target of $10.
Bears say
LifeMD is a relatively new company heavily focused on expanding their market through investments in new products and technologies. Despite their potential growth, there are concerns about their reliance on a single segment, as well as potential regulatory actions surrounding the use of peptides. Additionally, there are risks involved with the telemedicine industry, including cybersecurity threats and product recalls, which could hinder their growth. While the company has recently turned EBITDA-positive and has seen impressive growth, there is still uncertainty surrounding their future success in the highly regulated healthcare market.
This aggregate rating is based on analysts' research of LifeMD and is not a guaranteed prediction by Public.com or investment advice.
LifeMD (LFMD) Analyst Forecast & Price Prediction
Start investing in LifeMD (LFMD)
Order type
Buy in
Order amount
Est. shares
0 shares